{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-026938","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.967927+00:00","generated_at":"2026-05-17T13:02:29.535229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Talphera Q2 net loss $3.5M ($0.10/sh); NEPHRO study enrollment accelerates","bullets":["15 patients enrolled in NEPHRO registrational study; on track for completion by end of 2025, PMA submission Q1 2026.","Cash and equivalents $6.8M at June 30, 2025; closed $4.9M first tranche of $14.8M financing.","Net loss from continuing ops $3.5M vs $3.8M YoY; combined R&D/SG&A expenses $3.7M vs $4.3M.","Reduced 2025 cash operating expense guidance to $16M-$17M from prior $17M-$19M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-026938","json":"https://secwatch.observer/filing/0001437749-25-026938.json","markdown":"https://secwatch.observer/filing/0001437749-25-026938.md","text":"https://secwatch.observer/filing/0001437749-25-026938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925026938/0001437749-25-026938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925026938/acrx20250813_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:02:29.535229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}